Bosh sahifaNVV1 • FRA
add
Novavax Inc
Yopilish kursi
7,75 €
Kunlik diapazon
7,65 € - 7,78 €
Yillik diapazon
4,56 € - 9,00 €
Bozor kapitalizatsiyasi
1,52 mlrd USD
Oʻrtacha hajm
3,93 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Bozor yangiliklari
.DJI
1,66%
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 70,44 mln | -16,64% |
Joriy xarajat | 46,12 mln | -42,92% |
Sof foyda | -202,38 mln | -66,84% |
Sof foyda marjasi | -287,29 | -100,16% |
Har bir ulushga tushum | -1,25 | -64,47% |
EBITDA | -72,80 mln | 37,84% |
Amaldagi soliq stavkasi | 0,32% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 762,89 mln | -16,12% |
Jami aktivlari | 1,18 mlrd | -31,10% |
Jami passivlari | 1,34 mlrd | -40,30% |
Umumiy kapital | -156,67 mln | — |
Tarqatilgan aksiyalar | 162,50 mln | — |
Narxi/balansdagi bahosi | -8,08 | — |
Aktivlardan daromad | -15,77% | — |
Kapitaldan daromad | -110,07% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -202,38 mln | -66,84% |
Operatsiyalardan naqd pul | 107,80 mln | 174,44% |
Sarmoyadan naqd pul | -136,53 mln | -527,83% |
Moliyadan naqd pul | 42,44 mln | 43 854,64% |
Naqd pulning sof oʻzgarishi | 14,38 mln | 113,44% |
Boʻsh pul | 96,84 mln | 223,39% |
Haqida
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
Tashkil etilgan
1987
Sayt
Xodimlar soni
952